News

  1. SGD Pharma Commits To Near-Term Science Based Targets Initiative As Part Of Sustainability Drive 11/7/2023

    SGD Pharma, the global market leader in molded glass packaging solutions for the pharmaceutical industry, announces its commitment to company-wide emissions reductions as part of its decarbonization strategy by joining the Science Based Targets initiative (SBTi).

  2. BD To Showcase Its Commitment To Drug Delivery And Packaging Innovation At CPhI 2023 Conference 10/18/2023
  3. SHL Medical And Lifecore Biomedical Enter Co-Marketing Partnership Agreement 10/17/2023

    The partnership allows the companies to provide their customers unparalleled guidance in CDMO services and best-in-class options for drug delivery device development.

  4. SGD Pharma Continues To Innovate With The Extension Of Its Ready-To-Use Sterinity Glass Vials For Parenteral Pharmaceutical Applications, Adding 10ml And 20ml To Its ISO Portfolio 10/11/2023

    Global market leader in molded glass packaging solutions for the pharmaceutical industry, SGD Pharma announces the latest expansion of its Sterinity range of Ready-To-Use (RTU) Type I molded glass vials. The launch of additional sizes 10H*ml and 20H ml in tray is advantageous to customers who will benefit from increased flexibility as a result of the extended portfolio.

  5. Ocular Therapeutix™ Announces Initiation Of Its First Pivotal Clinical Trial of OTX-TKI In Wet AMD 10/11/2023

    Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the initiation of its first pivotal clinical trial to evaluate OTX-TKI, the Company’s axitinib intravitreal implant, for the treatment of wet age-related macular degeneration (wet AMD). OTX-TKI is also being developed for the treatment of diabetic retinopathy and other retinal diseases.

  6. Enable Injections Receives First U.S. Food And Drug Administration (FDA) Approval 10/2/2023

    Enable Injections, Inc. (“Enable”) today announced that the U.S. Food and Drug Administration (FDA) has approved the  EMPAVELI Injector (enFuse®) for the subcutaneous delivery of EMPAVELI® (pegcetacoplan), which is commercialized in the United States by Apellis Pharmaceuticals, Inc. for adults with paroxysmal nocturnal hemoglobinuria (PNH). The EMPAVELI Injector is a compact, wearable injector designed to streamline the self-administration experience with minimal disruption to patients’ daily lives.

  7. Sharps Technology Signs Asset Purchase Agreement To Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility And A 10-Year Purchase Agreement For Over $400 Million From Nephron Pharmaceuticals 9/27/2023

    Sharps Technology, Inc., an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, and Nephron Pharmaceuticals Corporation, a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility. This includes a 10-Year purchase agreement for over $400 Million from Nephron Pharmaceuticals for next-generation copolymer prefillable syringe systems. Product delivery is scheduled for the first quarter of 2024 with revenue totaling approximately $30 Million for the first twelve months of production and subsequent revenue of over $45 Million per year beginning in 2025, and continuing through 2033.

  8. CPHI Barcelona Announces Pharma Award Finalists 9/15/2023

    The shortlist was whittled down from more than 180 entries across 12 categories. Innovations cover the full pharmaceutical supply chain and feature many of pharma’s biggest names and breakthrough companies.

  9. Melbourne-Developed Drug Delivery Platform Delivers 'Impressive' Results In International Bowel And Ovarian Cancer Trial 9/12/2023

    A ground-breaking nanoscale drug delivery technology used to enhance the safety and performance of cancer drugs has been credited with “impressive” results in two of Australia’s most common cancers – colorectal (bowel) and ovarian cancer.

  10. Otsuka Collaborates With ShapeTX To Develop Novel AAV Gene Therapies For Ocular Diseases 9/7/2023

    Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types.